Abstract

BackgroundPentavalent antimonial-based chemotherapy is the first-line approach for leishmaniasis treatment and disease control. Nevertheless antimony-resistant parasites have been reported in some endemic regions. Treatment refractoriness is complex and is associated with patient- and parasite-related variables. Although amastigotes are the parasite stage in the vertebrate host and, thus, exposed to the drug, the stress caused by trivalent antimony in promastigotes has been shown to promote significant modification in expression of several genes involved in various biological processes, which will ultimately affect parasite behavior. Leishmania (Viannia) guyanensis is one of the main etiological agents in the Amazon Basin region, with a high relapse rate (approximately 25%).MethodsHerein, we conducted several in vitro analyses with L. (V.) guyanensis strains derived from cured and refractory patients after treatment with standardized antimonial therapeutic schemes, in addition to a drug-resistant in vitro-selected strain. Drug sensitivity assessed through Sb(III) half-maximal inhibitory concentration (IC50) assays, growth patterns (with and without drug pressure) and metacyclic-like percentages were determined for all strains and compared to treatment outcomes. Finally, co-cultivation without intercellular contact was followed by parasitic density and Sb(III) IC50 measurements.ResultsPoor treatment response was correlated with increased Sb(III) IC50 values. The decrease in drug sensitivity was associated with a reduced cell replication rate, increased in vitro growth ability, and higher metacyclic-like proportion. Additionally, in vitro co-cultivation assays demonstrated that intercellular communication enabled lower drug sensitivity and enhanced in vitro growth ability, regardless of direct cell contact.ConclusionsData concerning drug sensitivity in the Viannia subgenus are emerging, and L. (V.) guyanensis plays a pivotal epidemiological role in Latin America. Therefore, investigating the parasitic features potentially related to relapses is urgent. Altogether, the data presented here indicate that all tested strains of L. (V.) guyanensis displayed an association between treatment outcome and in vitro parameters, especially the drug sensitivity. Remarkably, sharing enhanced growth ability and decreased drug sensitivity, without intercellular communication, were demonstrated.Graphical

Highlights

  • Pentavalent antimonial-based chemotherapy is the first-line approach for leishmaniasis treatment and disease control

  • Six L. (V.) guyanensis strains obtained from cutaneous leishmaniasis patients before Sb(V) treatment were selected according to treatment outcome: three from cured patients (IOC-L2335, Instituto Oswaldo Cruz (IOC)-L2370, and IOC-L2960) and three from patients with treatment failure (IOCL2354, IOC-L2371, and IOC-L2372)

  • Therapeutic failure and in vitro‐derived resistance phenotypes are associated with reduced sensitivity to antimonials Leishmania (V.) guyanensis strains obtained from patients who were considered cured or who failed treatment will be referred to as C or F, respectively

Read more

Summary

Introduction

Pentavalent antimonial-based chemotherapy is the first-line approach for leishmaniasis treatment and disease control. Antimony-resistant parasites have been reported in some endemic regions. Leishmania (Viannia) guyanensis is one of the main etiological agents in the Amazon Basin region, with a high relapse rate (approximately 25%). Leishmaniasis is a complex of vector-borne diseases caused by parasites in the Leishmania genus and transmitted by phlebotomine sand flies. (V.) guyanensis are the main etiological agents of ATL [2], and both species are already associated with the mucosal form of the disease [3]. Amphotericin B, pentamidine, and miltefosine were recently incorporated as treatment agents for ATL, antimonial-derived drugs have been the primary treatment alternatives for more than 70 years [4, 5]. Antimonials display remarkable limitations, such as severe side effects and parasite resistance emergence, leading to treatment failure. Treatment failure has already been observed in many regions of the globe, such as Iran, India, and the Middle East [6,7,8,9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call